Use of hypoxia-directed drugs in the therapy of solid tumors

Seminars in Oncology

Volumn 19, Issue 4 SUPPL. 11, 1992, Pages 29-40

  Rockwell, Sara ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; DICOUMAROL; FLUORINE 18; FLUOROURACIL; METHOTREXATE; MISONIDAZOLE; MITOMYCIN C; OXYGEN; PORFIROMYCIN; RADIOSENSITIZING AGENT; SUPEROXIDE; TRITIUM;

CELL METABOLISM; CELL PH; CONFERENCE PAPER; DNA DAMAGE; HUMAN; HYPERBARIC OXYGEN; HYPOXIC CELL; NONHUMAN; NUTRITION; OXYGEN TENSION; PRIORITY JOURNAL; RADIOSENSITIZATION; SOLID TUMOR; TUMOR GROWTH;

ALKYLATING AGENTS; ANIMAL; CELL HYPOXIA; HUMAN; NEOPLASMS; OXIDATION-REDUCTION; SUPPORT, NON-U.S. GOV'T;

EID: 0026698228     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. The forty year old mutation theory of Luria and Delbruck and its pertinence to cancer chemotherapy
2. Radiotherapy: Mechanisms of action and radioresistance
3. The radioresponsiveness of human tumours and the initial slope of the cell survival curve
4. Radiosensitivity of late recurrences following radiotherapy of murine fibrosarcomas
5. 95 radiation dose
6. X-ray-induced heritable damage (smallcolony formation) in cultured mammalian cells
7. Production of radioresistant mutants in murine L5178Y lymphoma cells
8. Radioresistant mutants of L5178Y cells
9. Radiobiologic basis of oxygen as a modifying factor in radiation therapy
10. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy
11. La Ronde—radiation sciences and medical radiology
12. Tumor hypoxia: Its impact on cancer therapy
13. Hypoxic fractions of human tumors xenografted into mice: A review
14. The histological structure of some human lung cancers and the possible implications for radiotherapy
15. Intermittent blood flow in a murine tumor: Radiobiological effects
16. The phenomenon of reoxygenation and its implications for fractionated radiotherapy
17. Modification of radiation response
18. The relevance of tumour pH to the treatment of malignant disease
19. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review
20. Hypoxic cells as specific drug targets for chemotherapy
21. Microenvironmental changes in irradiated tumors
22. 31P nuclear magnetic resonance study of a human colon adenocarcinoma cultured cell line
23. 31P nuclear magnetic resonance evidence for the regulation of intracellular pH by Ehrlich ascites tumor cells
24. Applicability of animal tumor data to cancer therapy in humans
25. Effect of various oxygenation conditions and Fluosol-DA on cancer chemotherapeutic agents
26. Effects of a perfluorochemical emulsion on the response of BA1112 rat rhabdomyosarcomas to continuous low dose rate irradiation
27. Perfluorochemicals and hyperbaric oxygen in radiation therapy
28. Tumour cords in 52 human bronchial and cervical squamous cell carcinomas: Inferences for their cellular kinetics and radiobiology
29. Vascularization of tumors: A review
30. Intracapillary oxyhemoglobin saturation of malignant tumors in humans
31. Pathophysiological approaches to identifying tumor hypoxia in patients
32. 3H-misonidazole to solid human tumors as a measure of tumor hypoxia
33. Measurement of tumor hypoxia by invasive and non-invasive procedures: A review of recent clinical studies
34. Imaging of hypoxia in human tumors with [F-18] fluoromisonidazole
35. 2 tension measurements
36. Oxygen distribution of squamous cell carcinoma metastases and its relationship to outcome of radiation therapy
37. Changes in tumor oxygen tension during radiation therapy
38. Soft-tissue sarcomas: Detection of metabolic heterogeneity with P-31 MR spectroscopy
39. The effect of arterial oxygen content on the results of radiation therapy for epidermoid bronchogenic carcinoma
40. Definitive evidence for hypoxic cells influencing cure in cancer therapy
41. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: Results of a retrospective study of 386 patients
42. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: Report from the DAHANCA 2 study
43. Anaemia as a prognostic factor for the therapeutic effect of radiosensitizers
44. Positive clinical experience with misonidazole in brachytherapy and external radiotherapy
45. Carcinoma of the cervix-anaemia, radiotherapy and hyperbaric oxygen
46. Hyperbaric oxygen and radiotherapy: A Medical Research Council trial in carcinoma of the cervix
47. Does hyperbaric oxygen have a future in radiation therapy?
48. What have we learned from hyperbaric oxygen?
49. Fluosol and hyperbaric oxygen as an adjunct to radiation therapy in the treatment of malignant gliomas: A pilot study
50. A phase I/ II study of the use of Fluosol as an adjunct to radiation therapy in the treatment of primary high-grade brain tumors
51. Therapeutic advantage of hypoxic cells in tumors: A theoretical study
52. Preliminary results of bladder carcinoma irradiated with low individual doses and a high total dose
53. Reduced oxygen enhancement ratio at low doses of ionizing radiation
54. The variation of OER with dose rate
55. Influence of extracellular pH on intracellular pH and cell energy status: Relationship to hyperthermic sensitivity
56. Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer
57. Concurrent chemoradiation in advanced cervical cancer
58. Epidermoid anal cancer: Treatment by radiation and 5-fluorouracil with or without mitomycin C
59. Adjuvant chemotherapy in head and neck cancer
60. Combined modality treatment with radiotherapy and chemotherapy
61. The hypoxic tumor cell: A target for selective cancer chemotherapy
62. Therapeutic attack of hypoxic cells of solid tumors: Presidential address
63. Hypoxic cells as targets for cancer chemotherapy
64. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells
65. Acid pH in tumors and its potential for therapeutic exploitation
66. Cytotoxicity of compounds that interfere with the regulation of intracellular pH: A potential new class of anticancer drugs
67. Diarysulfonylureas and radiotherapy I. In vitro studies with N-(5-indanyl-sulfonyl)-N′-(4-chlorophenyl)-urea (Sulofenur)
68. Biochemistry of reduction of nitroheterocycles
69. Nitroheterocyclic compounds as radiation sensitizers and bioreductive drugs
70. Metabolism of SR 4233 by Chinese hamster ovary cells: Basis of selective hypoxic cytotoxicity
71. Bioactivation as a model for drug design bioreductive alkylation
72. Metabolism and reactions of quinoid anticancer agents
73. Synthesis and evaluation of some nitrobenzenesulfonamides containing nitroisopropyl and ureidooxymethyl groups as novel hypoxic cell selective cytotoxic agents
74. Failure of 5-thio-d-glucose to alter cell survival in irradiated or unirradiated EMT6 tumors
75. Mitomycin C and radiation
76. Preclinical studies with new mitomycin analogs
77. Preclinical studies of porfiromycin as an adjunct to radiotherapy
78. Effect of deficiencies in DNA repair on the toxicity of mitomycin C and porfiromycin to CHO cells under aerobic and hypoxic conditions
79. Activity of C-7 substituted cyclic acetal derivatives of mitomycin C and porfiromycin against hypoxic and oxygenated EMT6 carcinoma cells in vitro and in vivo
80. 3H]-porfiromycin adducts of EMT6 mouse mammary tumor cell DNA: Effects of hypoxia and dicumarol on adduct patterns
81. Cytotoxicity and DNA-crosslinks produced by mitomycin analogs in aerobic and hypoxic EMT6 cells
82. NADPH cytochrome p-450 reductase activation of quinone anticancer agents to free radicals
83. Mitomycin C-enhanced superoxide and hydrogen peroxide formation in rat heart
84. Modification of the cytotoxic activity of mitomycin C by oxygen and ascorbic acid in Chinese hamster ovary cells and a repair-deficient mutant
85. Effects of caffeine on L-cells exposed to mitomycin C
86. pH dependence of mitomycin C-induced crosslinking activity in EMT6 tumor cells
87. Effects of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cells in vitro
88. Diversity of penetration of anti-cancer agents into solid tumours